Portola Pharmaceuticals, Inc.
270 E. Grand Avenue
South San Francisco
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Stock Exchange: NASDAQ
Stock Symbol: PTLA
226 articles with Portola Pharmaceuticals, Inc.
Portola Presents Interim Phase IIa Safety And Efficacy Data For Cerdulatinib At The International Congress Of Malignant Lymphoma
Portola To Announce Fourth Quarter And Year-End 2016 Financial Results And Host Conference Call On Tuesday, February 28
FDA Informs Portola At Mid-Cycle Review For Betrixaban That It Has Not Identified Issues That Require An Advisory Committee Meeting
Portola Announces FDA Accepts New Drug Application For Priority Review And EMA Validates Marketing Authorization Application For Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
Dermavant Sciences Announces Licensing Of Topical Cerdulatinib From Portola For Dermatologic Indications
Portola Enters Into $50 Million Loan Agreement With Bristol-Myers Squibb And Pfizer For Continued Development Of Andexxa (Andexanet Alfa)
Portola Announces Andexxa™ (Andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society of Hematology Annual Meeting And Exposition
Portola Announces Three Phase III APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban
Portola Expands Clinical Collaboration Agreement With Daiichi Sankyo Worth Up To $25 Million To Develop Andexxa (Andexanet Alfa) In Germany
Portola To Announce Third Quarter 2016 Financial Results And Host Conference Call On Monday, November 7
Portola Submits New Drug Application To FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients
Portola Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting